research use only
Cat.No.S5246
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease |
|---|---|
| Other Reverse Transcriptase Inhibitors | Dapivirine (TMC120) Fangchinoline 3'-Fluoro-3'-deoxythymidine (Alovudine) Salicylanilide Bifendate Ulonivirine Islatravir Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride |
|
In vitro |
DMSO
: 55 mg/mL
(198.35 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 277.28 | Formula | C12H15N5O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 142217-69-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | BMS200475,SQ34676 | SMILES | C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
For treatment of hepatitis B virus, combinations of ETV with each of the other HBV NRTI antivirals, adefovir, tenofovir, and lamivudine at 10 times their respective Cmax levels fails to result in cellular or mitochondrial toxicity, and displays no DNA polymerase gamma inhibition. |
|---|---|
| In vivo |
Treatment with Entecavir in combination with AIC649, Induces tightly regulated Immunological and virological responses during active and maintenance ereatment in the woodchuck model of chronic hepatitis B. |
References |
(data from https://clinicaltrials.gov, updated on 2026-01-16)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07345624 | NOT_YET_RECRUITING | Hepatitis B Virus Infection; Children; Chronic Hepatitis B |
Qing-Lei Zeng |
2026-01-11 | PHASE4 |
| NCT07345611 | NOT_YET_RECRUITING | Hepatitis B Virus Infection; Children; Chronic Hepatitis B |
Qing-Lei Zeng |
2026-01-11 | PHASE4 |
| NCT07493109 | RECRUITING | Diffuse Large B-Cell Lymphoma (DLBCL) |
Ou Bai, MD/PHD |
2026-05-30 | PHASE3 |
| NCT04942886 | ENROLLING_BY_INVITATION | Hepatitis B Reactivation; Hematopoietic Stem Cell Transplantation; Antiviral Drug; HBV |
Seoul St. Mary's Hospital |
2021-08-21 | |
| NCT07797231 | NOT_YET_RECRUITING | Chronic Hepatitis B |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2026-09 | PHASE3 |
| NCT05905172 | RECRUITING | Liver Fibrosis |
Beijing Continent Pharmaceutical Co, Ltd. |
2023-08-12 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.